NeuroOne Medical Technologies Corp [NMTC] stock is trading at $0.93, up 3.34%. An important factor to consider is whether the stock is rising or falling in short-term value. The NMTC shares have gain 4.60% over the last week, with a monthly amount glided 23.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NeuroOne Medical Technologies Corp [NASDAQ: NMTC] stock has seen the most recent analyst activity on May 05, 2025, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $1.45. Previously, Craig Hallum downgraded its rating to Hold on March 29, 2022, and dropped its price target to $2.
NeuroOne Medical Technologies Corp [NMTC] stock has fluctuated between $0.40 and $1.39 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. NeuroOne Medical Technologies Corp [NASDAQ: NMTC] shares were valued at $0.93 at the most recent close of the market. An investor can expect a potential return of 222.58% based on the average NMTC price forecast.
Analyzing the NMTC fundamentals
NeuroOne Medical Technologies Corp [NASDAQ:NMTC] reported sales of 9.63M for the trailing twelve months, which represents a growth of 105.39%. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at -0.86%, Pretax Profit Margin comes in at -0.81%, and Net Profit Margin reading is -0.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.63 and Total Capital is -0.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, NeuroOne Medical Technologies Corp’s Current Ratio is 7.13. On the other hand, the Quick Ratio is 5.80, and the Cash Ratio is 5.64. Considering the valuation of this stock, the price to sales ratio is 4.83, the price to book ratio is 5.67.
Transactions by insiders
Recent insider trading involved Christianson Mark, Business Development Director, that happened on Sep 05 ’25 when 30000.0 shares were sold. Officer, Christianson Mark completed a deal on Aug 20 ’25 to buy 30000.0 shares. Meanwhile, Business Development Director Christianson Mark sold 10000.0 shares on Jun 04 ’25.
